Home » EMA Accepts File for AstraZeneca PARP Inhibitor
EMA Accepts File for AstraZeneca PARP Inhibitor
The EMA has accepted a marketing authorization application from AstraZeneca for olaparib, a PARP inhibitor targeting BRCA-mutated platinum-sensitive serous ovarian cancer.
Pharma Times
Pharma Times
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May